Campylobacter jejuni strain CG8421: A refined model for the study of campylobacteriosis and evaluation of campylobacter vaccines in human subjects

Clinical Infectious Diseases

Volumn 49, Issue 10, 2009, Pages 1512-1519

  Tribble, David R ^a,b   Baqar, Shahida ^a,b   Carmolli, Marya P ^c   Porter, Chad ^a   Pierce, Kristen K ^c   Sadigh, Katrin ^c   Guerry, Patricia ^a   Larsson, Catherine J ^c   Rockabrand, David ^a   Ventone, Cassandra H ^c   Poly, Frederic ^a   Lyon, Caroline E ^c   Dakdouk, Sandra ^a   Fingar, Ann ^c   Gilliland Jr , Theron ^a   Daunais, Patrick ^c   Jones, Erika ^a   Rymarchyk, Stacia ^c   Huston, Christopher ^c   Darsley, Michael ^d   Kirkpatrick, Beth D ^c   more..

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d ACE BioSciences AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL VACCINE; CAMPYLOBACTER VACCINE; GAMMA INTERFERON; GANGLIOSIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LIPOOLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ANTIBIOTIC RESISTANCE; ANTIBODY DETECTION; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG SCREENING; DYSENTERY; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; DIARRHEA; DRUG EVALUATION; FECES; FEMALE; HUMAN EXPERIMENTATION; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 72849112054     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/644622     Document Type: Article

References (24)

1. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001; 32:1201-6
2. Altekruse SF, Stern NJ, Fields PI, Swerdlow DL. Campylobacter jejunian emerging foodborne pathogen. Emerg Infect Dis 1999; 5:28-35.
3. Glass RI, Stoll BJ, Huq MI, Struelens MJ, Blaser M, Kibriya AK. Epidemiologic and clinical features of endemic Campylobacter jejuni infection in Bangladesh. J Infect Dis 1983; 148:292-6.
4. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of travelers diarrhea in Jamaica. Jama 1999; 281:811-7.
5. Tribble DR, Sanders JW, Pang LW, et al. Travelers diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338-46.
6. Kaldor J, Speed BR. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br Med J (Clin Res Ed) 1984; 288:1867-70.
7. Rhodes KM, Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter infection. Br Med J (Clin Res Ed) 1982; 285:173-4.
8. Black R, Levine MM, Clements ML, Hughes TP, Blaser MJ. Human Volunteer studies with Campylobacter jejuni. In: Campylobacter jejuni: current status and future trends. Washington, DC: American Society of Microbiology, 1992:207-15.
9. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis 1988; 157:472-9.
10. Tribble D, Baqar S, Scott D, et al. Campylobacter jejuni experimental infection in humans: assessment of duration of protection. Infect Immun (in press).
11. Guerry P, Szymanski CM, Prendergast MM, et al. Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro. Infect Immun 2002; 70:787-93.
12. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25:61-6.
13. Ang CW, Noordzij PG, de Klerk MA, Endtz HP, van Doorn PA, Laman JD. Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits. Infect Immun 2002; 70:5081-5.
14. Prendergast MM, Tribble DR, Baqar S, et al. In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Infect Immun 2004; 72:916-22.
15. Poly F, Read T, Chen Y-H, et al. Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies. Infect Immun 2008; 76:5655-67.
16. Levine MM, Bergquist EJ, Nalin DR, et al. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet 1978; 1:1119-22.
17. Baqar S, Applebee LA, Bourgeois AL. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infect Immun 1995; 63:3731-5.
18. Pennie RA, Pearson RD, Barrett LJ, Lior H, Guerrant RL. Susceptibility of Campylobacter jejuni to strain-specific bactericidal activity in sera of infected patients. Infect Immun 1986; 52:702-6.
19. Baqar S, Rice B, Lee L, et al. Campylobacter jejuni enteritis. Clin Infect Dis 2001; 33:901-5.
20. Murphy JR, Baqar S, Munoz C, et al. Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions. J Infect Dis 1987; 156:1005-9.
21. Baqar S, Tribble D, Carmolli MP, et al. Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well characterized organism. Clinical Vaccine Immunology (in press).
22. Poly F, Guerry P. Pathogenesis of Campylobacter. Curr Opin Gastroenterol 2008; 24:27-31.
23. Louwen R, Heikema A, van Belkum A, et al. The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. Infect Immun 2008; 76:4431-8.
24. Guidance for Industry. E6 Good clinical practice: consolidated guidance US Department of Health and Human Services. Food and Drug Administration. CDER, 1996. Available at: http://www.fda.gov/cder/guidance/959fnl.pdf. Accessed 3 April 2009